


Consensus Conference on Histopathology and Therapy of GVHD Regensburg

18. - 19. November 2011



Dept. of Hematology and Oncology
Stem Cell Transplantation Program
&
Institute of Pathology

University of Regensburg

Organisation: E. Holler, D. Wolff, F. Hofstädter, R. Andreesen

Gefördert von:

joséCARRERAS
LEUKÄMIE-STIFTUNG



Dear colleagues,

we are pleased to invite you to the Consensus Conference on Histopathology and Therapy of GVHD 2011 held in Regensburg. Acute and chronic GVHD continues to be a challenge in clinical practice balancing GVHD treatment against toxicity and infectious morbidity. While GVHD is often regarded as clinical diagnosis without further need of histological confirmation numerous differential diagnoses have to be considered which in part require differential treatment. Since GVHD and its treatment are associated with significant morbidity and mortality the diagnosis requires a high level of certainty. Therefore, histopathological confirmation is of major importance. The Consensus Conference on Histopathology of GVHD is aiming to provide guidance for histopathological diagnosis of GVHD in clinical practice. Moreover, the consensus will be the basis of further research activities to improve histopathological diagnosis of GVHD. An additional topic is the histopathological grading of GVHD in murine models. The latter are an important source of knowledge on pathophysiology of GVHD. Despite of its importance, standardized criteria of experimental GVHD are mainly lacking. The consensus conference aims to provide the basis for standardized evaluation of GVHD in murine models on GVHD. Furthermore, treatment options of acute GVHD will be discussed focusing on the currently available literature and clinical experience to provide recommendations for use of different immunosuppressive / immunomodulatory strategies in clinical practice.

H. Greinix, F. Wrba, J. Stift, A. Lawitschka (Wien)

A. Schmitt-Gräff, H. Bertz (Freiburg)

J. Halter (Basel)

J. U. Hillen (Essen), M. Ziemer (Leipzig)

F. Länger (Hannover)

A. Nogai, L. Uharek (Berlin)

F. Ayuk (Hamburg)

R. Schwerdtfeger (Wiesbaden)

E. Holler, M. Edinger, R. Andreesen, F. Hofstädter, E. Huber, D. Wolff (Regensburg)

Friday, 18.11.2011

- 9.00 – 12.00** **Meeting of the Working Group Murine Pathohistology**
(“Mikroskopiersaal” Pathology)
(E. Ullrich (Erlangen), A. Nogai (Berlin), E. Huber, M. Edinger (Regensburg))
- 9.00 – 11.30** **Business Meeting of the GVHD Group**
(“Seminarraum” Pathology 1st Floor)
(update and discussion of future projects)
- 11.00 – 12.30** **Lunch**
- 12.30 – 13.00** **Opening („Großer Hörsaal“)**
R. Andreesen, E. Holler, F. Hofstädter
- 13.00 – 14.30** **Joint Session**
Clinical Aspects of Histopathology in Diagnosis and Treatment of GVHD
Chair: E. Holler, H. Shulman (Seattle), S. Pavletic (Bethesda)
- 13.00 - 13.30 Standardized diagnosis of GVHD (S. Pavletic)
13.30 - 14.00 Histopathology in GVHD–definition of the target (H. Shulman)
14.00 - 14.30 Role of histopathology in clinical diagnosis of GVHD (D. Wolff)
- 14.30 – 15.00** **Coffee break**
- 15.00 – 18.30** **Meeting of the subcommittees**
Cutaneous GVHD
(“Diskussionsmikroskopierraum” / Library Pathology 2nd Floor)
Chair: J.U. Hillen (Essen), A. Janin (Paris), A. Lawitschka (Wien), D. Massi (Florenz)
- Intestinal GVHD
(“Mikroskopiersaal” Pathology)
Chair: A. Schmitt-Graeff (Freiburg), D. Kleiner (Bethesda), E. Holler (Regensburg), W. Kreisler (Freiburg)

Liver GVHD GVHD

(„Diskussionsmikroskopierraum“ 2nd Floor / „Seminarraum“ Pathology 1st Floor)

Chair: F. Wrba (Wien), H. Shulman (Seattle), R. Schwerdtfeger (Wiesbaden)

Lung GVHD

(Library Pathology 2nd Floor)

Chair: F. Länger (Hannover), G. Hildebrandt (Shreveport), S. Pavletic (Bethesda)

15.00 – 18.45

Treatment of acute GVHD (Kleiner Hörsaal)

Chair: F. Ayuk (Hamburg), J. Halter (Basel), D. Wolff (Regensburg)

- 15.00 - 15.20 Role of Steroids and CNI in Treatment of a GVHD (F. Ayuk)
- 15.20 - 15.40 Role of ATG (I. Hilgendorf)
- 15.45 - 16.00 Role of ECP (H. Greinix)
- 16.00 - 16.15 Role of MMF (A. Elmaagacli)
- 16.15 - 16.30 Role of mTOR-Inhibitors (M. Schleuning)

16.30 - 17.00

Coffee break

- 17.00 - 17.15 Role of cellular products (M. Edinger)
- 17.15 - 17.30 Role of antibodies incl. TNF-Blockade (A. Gerbitz)
- 17.30 - 17.45 Role of Pentostatin (S. Klein)
- 17.45 - 18.00 Pre-GvHD-Trial (E. Weissinger)
- 18.00 - 18.15 Results of the survey on treatment of acute GVHD (D. Wolff)
- 18.15 - 18.30 GVHD-Registrier (R. Meyer)

Welcome reception

Location: „Leerer Beutel“

Bertoldstraße 9

93047 Regensburg

www.leerer-beutel.de

Saturday 19.11.2011 Presentation of the Consensus

- 8.30 – 9.30** **Histopathology in Murine Models** (Kleiner Hörsaal)
Chair: M. Edinger (Regensburg), A. Nogai (Berlin)
- 8.30 - 8.45 Clinical scoring / strain –model specific aspects (E. Ullrich)
8.45 - 9.00 Histopathological scoring liver and lung (E. Huber)
9.00 - 9.15 Histopathological scoring skin and gut (R. Klopffleisch)
9.15 - 9.30 Migration of immune cells and correlation with histopathology (R. Zeiser)
- 9.30 – 10:15** **Histopathological Diagnosis of Cutaneous GVHD**
Chair: A. Janin (Paris), M. Ziemer (Leipzig)
- 09.30 - 09.45 Indication, localisation and technique for skin biopsies (U. Hillen)
09.45 - 10.05 Histopathological evaluation (M. Ziemer)
- 10.05 - 10.15** **Discussion**
- 10.15 – 10.30** **Coffee break**
- 10.30 – 11.15** **Histopathological Diagnosis of Intestinal GVHD**
Chair: E. Holler (Regensburg), D. Kleiner (Bethesda)
- 10.30 - 10.45 Indication, localisation and technique for GI biopsies (E. Holler)
10.45 - 11.05 Histopathological evaluation (A. Schmitt-Graeff)
- 11.05 - 11.15** **Discussion**
- 11.15 - 12.00** **Histopathological Diagnosis of Liver GVHD**
Chair: F. Wrba (Wien), H. Shulman (Seattle)
- 11.15 – 11.30 Indications and technique for biopsies in GVHD (R. Schwerdtfeger)
11.30 - 11.50 Histopathological evaluation (J. Stift)
- 11.50 - 12.00** **Discussion**

12.00 – 12.30	Histopathological Diagnosis of Lung GVHD Chair: F. Länger (Hannover), G. Hildebrandt (Shreveport)
12.00 - 12.15	Indication and techniques for histological diagnosis of GVHD (G. Hildebrandt)
12.15 - 12.30	Histopathological evaluation of lung biopsies (F. Länger)
12.30 – 13.15	Conclusion D. Kleiner, S. Pavletic, D. Wolff,
12.30 - 12.50	Consensus on histopathology beyond the NIH consensus (D. Kleiner)
12.50 - 13.15	Summary of the consensus and outlook (D. Wolff)
13.15	Lunch

Topics

- 1. Histopathology in clinical GVHD**
Role of histopathology in diagnosis and treatment of GVHD
Timing, location and technique of biopsies
Essential clinical information for histopathological evaluation
Processing of biopsies including essential and optional stains
Histopathological evaluation reports
Network of 2nd opinion pathologists
Future projects in histopathology of acute and chronic GVHD
- 2. Histopathology in experimental GVHD**
Processing of biopsies including essential and optional stains
Histopathological evaluation
- 3. Treatment of GVHD**
Treatment of acute GVHD (indication and options in 2nd line treatment)
GVHD-Registrar

Invited international participants:

Prof. Howard M. Shulman, MD
Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Department of
Pathology, University of Washington,
825 Eastlake Ave. E.
Seattle, WA 98109

Gerhard Hildebrandt, MD
Associate Professor of Medicine
LSU Health Sciences Center-Shreveport
Feist-Weiller Cancer Center
Blood and Marrow Transplant Program
1501 Kings Highway
Shreveport, LA
71130 USA

Prof. Anne Janin, MD
Service de Pathologie et ERM 0220 Inserm
Universite Paris VII, Institut Universitaire d'Hematologie
Hospital Saint Louis
1, avenue Vellefaux, 75 010 Paris

Prof. David Kleiner
Chief, Post Mortem Pathology, Division of Clinical Science
National Cancer Institute
10 Center Drive
Bethesda, MD 20892-1203

Daniela Massi, MD
Associate Professor of Pathology
Division of Pathological Anatomy, Dept. of Critical Care Medicine and Surgery
University of Florence
Viale G.B. Morgagni, 85
50134 Florence, Italy

Prof. Steven Z. Pavletic, MD
Head of GVHD and Autoimmunity Unit
Experimental Transplantation and Immunology Branch
Center of Cancer Research, National Cancer Institute
10 Center Drive, CRC, Room 4-3130
Bethesda, MD 20892-1203

Conference Venue

University Hospital Regensburg
Franz-Josef-Strauss-Allee 11
93053 Regensburg, Germany

General tourist and hotel information

Tourist-Information Altes Rathaus

Rathausplatz 4
93047 Regensburg
Germany

Tel.: +49-(0)941/507-4410

Tel.: +49-(0)941/507-4411

<http://www.tourismus.regensburg.de/tourismus/de/medienportal/1160>

Local Contact

Prof. Dr. Daniel Wolff
Dept. of Hematology and Oncology
University Hospital Regensburg
Franz-Josef-Strauß-Allee 11
93053 Regensburg

Tel.: +49- (0)941/944-5531

Fax: +49- (0)941/944-5543

Email: daniel.wolff@klinik.uni-regensburg.de

Registration Form

Please mail or fax to:

Susanna Blüml

Dept. of Hematology and Oncology

University of Regensburg

F.J. Strauss Allee 11, 93053 Regensburg, Germany

Phone: -49-941-944-5542

Fax: -49-941-944-5543

e-mail: Susanna.Blueml@klinik.uni-regensburg.de

Consensus Conference on Histopathology in GVHD Regensburg

18. - 19. November 2011

I want to participate at the consensus conference attending the meeting of the following subcommittees:

Treatment of acute GVHD

Histopathology of Murine GVHD

Histopathology of cutaneous GVHD

Histopathology of Intestinal GVHD

Histopathology of Liver GVHD

Histopathology of Lung GVHD

I will not be able to participate at the consensus conference

I need support with hotel reservation

Address:

Name: _____

Institution _____

Address _____

e-mail _____

Phone _____

Fax _____

Supported by:

AMGEN

Onkologie



Dr. Falk Pharma GmbH

MSD Sharp & Dohme GmbH

Johnson & Johnson Medical GmbH

Roche Pharma GmbH

Gilead Sciences GmbH

Riemser Arzneimittel AG

Alexion Pharma GmbH

Novartis Pharma GmbH